Bayer has restructured and expanded its ongoing partnership with Recursion Pharmaceuticals on artificial intelligence-powered drug discovery, switching to a focus on cancer via a revised deal that could be worth up to $1.5 billion.

拜耳已经重组并扩大了与Recursion Pharmaceuticals在人工智能药物研发方面的持续合作关系，通过可能价值高达15亿美元的修订协议转向关注癌症。

The two companies will now work on up to seven precision oncology projects, making use of Recursion’s drug discovery platform that draws on a dataset of five trillion biological and chemical relationships and combines wet-lab biology and chemistry with machine learning tools in a form of “digitised” drug discovery.

这两家公司现在将利用递归的药物发现平台，利用五万亿生物和化学关系的数据集，将湿实验室生物学和化学与机器学习工具结合起来，开展多达七个精确的肿瘤学项目。数字化“药物发现。

.

.

The dataset covers 50 different human cell types as well as a library of approximately 1.7 million small molecules and is supported by BioHive-1, a supercomputer operated by tech giant Nvidia, which invested $50 million in Recursion earlier this year.

该数据集涵盖了50种不同的人类细胞类型以及大约170万个小分子的库，并得到了由tech giant Nvidia运营的超级计算机BioHive-1的支持，该计算机今年早些时候投入了5000万美元的递归资金。

Under the terms of the new agreement, Bayer gets the option to exclusively license novel therapeutics derived from the programme.

根据新协议的条款，拜耳可以选择独家许可从该计划衍生的新疗法。

Bayer’s venture capital arm was a participant in Recursion’s $239 million Series D financing in 2020, leading the round with a contribution of $50 million that was accompanied by a five-year research collaboration focusing on fibrotic diseases and was expanded in 2021 to include up to 12 projects.

拜耳的风险投资部门于2020年参与了Recursion的2.39亿美元D系列融资，首轮捐款为5000万美元，伴随着一项针对纤维化疾病的五年研究合作，并于2021年扩大至包括12个项目。

That has now been wound up, but Bayer was clearly impressed by the technology deployed in the partnership and wants to tap into it for its oncology pipeline.

现在已经结束，但拜耳对合作伙伴关系中部署的技术明显印象深刻，并希望将其用于肿瘤学管道。

Juergen Eckhardt, the German group’s business development head, said it “could be one of the most disruptive technologies of our time.”

德国集团业务发展负责人Juergen Eckhardt表示，“可能是我们这个时代最具破坏性的技术之一。”

Recursion’s platform has attracted other big pharma clients, notably Roche/Genentech which signed up for a decade-long partnership in 2021 focusing on neuroscience and oncology drugs that involved a $150 million upfront payment and could be worth several billion dollars if fully exercised. That alliance recently generated its first ‘hit series’ for an undisclosed oncology target..

Recursion的平台吸引了其他大型制药客户，特别是罗氏/基因泰克公司（Roche/Genentech），该公司于2021年签署了长达十年的合作伙伴关系，专注于神经科学和肿瘤药物，涉及1.5亿美元的前期付款，如果充分行使，可能需要数十亿美元。该联盟最近为未公开的肿瘤学目标制作了第一个“命中系列”。。

“We believe that the next generation of biopharma leaders will operate at the convergence of rigorous science, scaled datasets and accelerated computing,” said Chris Gibson, co-founder and chief executive of Recursion.

“我们相信下一代生物制药领导者将在严谨的科学，规模化的数据集和加速计算的融合中运作，”递归的联合创始人兼首席执行官克里斯·吉布森（Chris Gibson）说。

The Bayer alliance highlights “the scale and broad-scale applicability of our platform…as we turn our focus together on challenging targets in oncology with the goal of bringing better medicines to patients more efficiently,” he added.

拜耳联盟强调“我们平台的规模和广泛适用性……当我们将重点放在肿瘤学的挑战性目标上，以更有效地为患者提供更好的药物时，”他补充说。

Alongside the new Bayer agreement, Recursion also announced a four-fold expansion of its allocation of computation capacity on BioHive-1, and an alliance with fellow AI drug discovery company Tempus Pharma giving it access to the latter’s proprietary, de-identified patient dataset in cancer, which spans DNA, RNA, health records and other data sources.

除了新的拜耳协议之外，递归还宣布将其在BioHive-1上的计算能力分配扩大四倍，并与AI药物发现公司Tempus Pharma合作，使其能够访问后者专有的，未识别的患者数据集癌症，涵盖DNA，RNA，健康记录和其他数据来源。

.

.

Recursion is paying up to $160 million to Tempus over the next five years in either cash or equity under the terms of the deal.

根据协议条款，递归在未来五年内以现金或股权支付高达1.6亿美元的速度。